RAP1GAP2

Across TCGA pan-cancer cohorts, RAP1GAP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAP1GAP2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAP1GAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAP1GAP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where RAP1GAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.819	0.533	.002	44	view →
PDAC	OS	Quartile	All	1.000	0.824	.001	22	view →
GBM	DFS	Tertile	All	0.275	0.490	.029	3	view →
LSCC	DFS	Median	All	0.726	0.866	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAP1GAP2–CCRCC (DFS)

Open the CCRCC breakdown →